Altretamine
Hexalen (altretamine) is a small molecule pharmaceutical. Altretamine was first approved as Hexalen on 1990-12-26. It is used to treat ovarian neoplasms in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| neoplasms | D009369 |
| urogenital diseases | D000091642 |
| endocrine system diseases | D004700 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Altretamine
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| HEXALEN | Eisai | N-019926 DISCN | 1990-12-26 | 1 products, RLD |
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| ovarian neoplasms | EFO_0003893 | D010051 | C56 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
64 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Erectile dysfunction | D007172 | EFO_0004234 | F52.21 | — | 1 | — | 1 | 4 | 6 |
| Arterial occlusive diseases | D001157 | EFO_0009085 | 1 | — | 1 | 1 | — | 3 | |
| St elevation myocardial infarction | D000072657 | — | — | — | 2 | — | 2 | ||
| Induced labor | D007751 | — | — | — | 2 | — | 2 | ||
| Obstetric labor complications | D007744 | — | 1 | 1 | 1 | — | 2 | ||
| Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | — | — | — | 1 | — | 1 |
| Ischemia | D007511 | EFO_0000556 | — | — | — | 1 | — | 1 | |
| Chronic renal insufficiency | D051436 | N18 | — | — | — | 1 | — | 1 | |
| Stroke | D020521 | EFO_0000712 | I63.9 | — | — | — | 1 | — | 1 |
| Diabetic nephropathies | D003928 | EFO_0000401 | — | — | — | 1 | — | 1 |
Show 8 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Heart failure | D006333 | EFO_0003144 | I50 | — | — | 1 | — | 1 | 2 |
| Prostatic neoplasms | D011471 | C61 | — | 1 | 1 | — | — | 2 | |
| Obesity | D009765 | EFO_0001073 | E66.9 | — | 1 | 1 | — | — | 1 |
| Labor pain | D048949 | — | — | 1 | — | — | 1 | ||
| Percutaneous coronary intervention | D062645 | — | — | 1 | — | — | 1 | ||
| Macular degeneration | D008268 | EFO_0001365 | H35.30 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pulmonary hypertension | D006976 | EFO_0001361 | I27.20 | — | 2 | — | — | 1 | 3 |
| Covid-19 | D000086382 | U07.1 | — | 1 | — | — | 1 | 2 | |
| Respiratory distress syndrome | D012128 | EFO_1000637 | J80 | — | 1 | — | — | 1 | 2 |
| Respiratory insufficiency | D012131 | HP_0002093 | J96.9 | — | 2 | — | — | — | 2 |
| Newborn respiratory distress syndrome | D012127 | P22 | — | 2 | — | — | — | 2 | |
| Extracorporeal membrane oxygenation | D015199 | — | 1 | — | — | — | 1 | ||
| Systemic scleroderma | D012595 | EFO_0000717 | M34 | — | 1 | — | — | — | 1 |
| Streptococcal infections | D013290 | EFO_1001476 | — | 1 | — | — | — | 1 | |
| Peripheral arterial disease | D058729 | EFO_0004265 | — | 1 | — | — | — | 1 | |
| Ischemic optic neuropathy | D018917 | EFO_1000809 | H47.01 | — | 1 | — | — | — | 1 |
Show 4 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Congenital heart defects | D006330 | HP_0001627 | Q24.9 | 1 | — | — | — | 1 | 2 |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | 1 | — | — | — | — | 1 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Penile neoplasms | D010412 | C60 | — | — | — | — | 1 | 1 | |
| Raynaud disease | D011928 | EFO_1001145 | I73.0 | — | — | — | — | 1 | 1 |
| Sleep | D012890 | GO_0030431 | — | — | — | — | 1 | 1 | |
| Psychological distress | D000079225 | — | — | — | — | 1 | 1 | ||
| Professional burnout | D002055 | — | — | — | — | 1 | 1 | ||
| Anxiety | D001007 | EFO_0005230 | F41.1 | — | — | — | — | 1 | 1 |
| Affect | D000339 | — | — | — | — | 1 | 1 | ||
| Pituitary acth hypersecretion | D047748 | EFO_1001110 | E24.0 | — | — | — | — | 1 | 1 |
| Pyloric stenosis | D011707 | K31.1 | — | — | — | — | 1 | 1 | |
| Mesenteric ischemia | D065666 | K55.1 | — | — | — | — | 1 | 1 |
Show 10 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | ALTRETAMINE |
| INN | altretamine |
| Description | Hexamethylmelamine is a triamino-1,3,5-triazine. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CN(C)c1nc(N(C)C)nc(N(C)C)n1 |
Identifiers
| PDB | — |
| CAS-ID | 645-05-6 |
| RxCUI | 5296 |
| ChEMBL ID | CHEMBL1455 |
| ChEBI ID | 24564 |
| PubChem CID | 2123 |
| DrugBank | DB00488 |
| UNII ID | Q8BIH59O7H (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 256 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
62,434 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more